Minimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire

Bennett, Robert M.; Bushmakin, Andrew G.; Cappelleri, Joseph C.; Zlateva, Gergana; Sadosky, Alesia

doi:10.3899/jrheum.081090

Cited by 320 publications

(269 citation statements)

References 28 publications

Supporting

Mentioning

248

Contrasting

Unclassified

Order By: Relevance

“…In other studies evaluating patients with comorbid MDD and fibromyalgia, the severity of depression was usually in the mild range (i.e., HAM-D score 10-15) with less severe impairment due to fibromyalgia (i.e., FIQ score Ͻ60) (20,39). The change from baseline to week 8 in the FIQ score meets the threshold for the minimal clinically important difference (14%) (46), supporting a meaningful improvement in fibromyalgia symptoms with quetiapine XR.…”

Section: Discussionmentioning

confidence: 98%

Quetiapine Fumarate Extended‐Release for the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome: A Double‐Blind, Randomized, Placebo‐Controlled Study

McIntyre

Paisley

Kouassi

et al. 2014

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective. Fibromyalgia and major depressive disorder (MDD) frequently co-occur. Quetiapine fumarate extended-release (quetiapine XR) has demonstrated efficacy in the treatment of MDD and has been shown to have analgesic properties in patients with depression. The primary objectives of this study were to evaluate the effects of quetiapine XR on depressive and pain symptoms in patients with MDD and comorbid fibromyalgia, and to assess its safety and tolerability. Results. The mean change in the HAM-D score from baseline to week 8 was significantly greater in the quetiapine XR group compared with the placebo group (؊10.0 versus ؊5.8; P ‫؍‬ 0.001). Improvements in most secondary outcomes were also significantly greater in the quetiapine XR group. Quetiapine XR was generally well tolerated.Conclusion. This study is the first to demonstrate that measures of depression, pain, and quality of life are significantly improved with quetiapine XR compared with placebo in patients with a dual diagnosis of MDD and fibromyalgia.Fibromyalgia is a syndrome characterized by widespread musculoskeletal pain that lasts at least 3 months, with a reduced pain threshold. Widespread pain is the defining feature of fibromyalgia. Associated symptoms include fatigue, sleep disturbance, stiffness, cognitive symptoms, and mood abnormalities including depression and anxiety (1,2). Pain, fatigue, and sleep disturbance are present in at least 75% of patients (3). The condition is estimated to occur in ϳ2-4% of the general adult population (4,5), and the prevalence is higher among women (4.9%) than men (1.6%) (6).Patients with fibromyalgia are at increased risk of mood disorders. Studies suggest that the prevalence of current depression among patients with fibromyalgia is as high as 22-40% (7), and that lifetime prevalence rates reach 58-86% (8,9). This high degree of co-occurrence is thought to be related in part to pathophysiologic abnormalities that are shared between fibroClinicalTrials.gov identifier: NCT00675896.

show abstract

Section: Discussionmentioning

confidence: 98%

Quetiapine Fumarate Extended‐Release for the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome: A Double‐Blind, Randomized, Placebo‐Controlled Study

McIntyre

Paisley

Kouassi

et al. 2014

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…However, a higher reduction rates in the FIQ score and BDI score have been suggested as clinically significant by some authors [28]. In a recent study by Yilmaz et al [29] including patients with chronic nonspecific widespread musculoskeletal pain, it was reported that replacement of vitamin D improved the quality of life (SF-36).…”

Section: Discussionmentioning

confidence: 99%

Effects of Vitamin D Therapy on Quality of Life in Patients with Fibromyalgia

Doğru¹,

Balkarlı²,

Çobankara³

et al. 2017

Eurasian J Med

View full text Add to dashboard Cite

Objective: The role of vitamin D in the etiopathogenesis of fibromyalgia and non-specific musculoskeletal pain is controversial. In our study, we aimed to investigate the effect of vitamin D therapy on quality of life in patients with fibromyalgia. Materials and Methods:Seventy patients diagnosed with fibromyalgia and 65 age-and sex-matched controls were included in the study. Patients were grouped as deficient (<20 ng/mL), inadequate (20-30 ng/mL), and sufficient (>30 ng/mL) according to the levels of vitamin D. Vitamin D replacement was performed for patients with deficiencies and inadequacies. Before and after vitamin D therapy, patients filled in the assessment tools, fibromyalgia impact questionnaire (FIQ), Arizona sexual experience scale (ASEX), Beck depression inventory (BDI), visual analog scale (VAS), and short form-36 (SF-36).Results: Vitamin D deficiencies and inadequacies were observed in 60% of the patients (n=42). Among patients with low and normal levels of vitamin D, no statistically significant difference was observed in their values. In scales examined after vitamin D replacement therapy, statistically significant differences were observed in the FIQ, BDI, VAS, and SF-36 compared with pre-treatment.

show abstract

“…Subjects' FIQ total scores were used to define fibromyalgia severity as follows: 0 to less than 39 = mild, 39 to less than 59 = moderate, and 59 to 100 = severe. 25 …”

Section: Patient Questionnaire and Assessment Of Fibromyalgia Severitymentioning

confidence: 99%

The Comparative Economic Burden of Mild, Moderate, and Severe Fibromyalgia: Results from a Retrospective Chart Review and Cross-Sectional Survey of Working-Age U.S. Adults

Chandran

Schaefer²,

Ryan³

et al. 2012

JMCP

Self Cite

View full text Add to dashboard Cite

show abstract

Minimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire

Abstract: The analysis indicates that a 14% change in the FIQ total score is clinically relevant, and results of these analyses should enhance the clinical utility of the FIQ in research and practice.

Cited by 320 publications

References 28 publications

Quetiapine Fumarate Extended‐Release for the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome: A Double‐Blind, Randomized, Placebo‐Controlled Study

Quetiapine Fumarate Extended‐Release for the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome: A Double‐Blind, Randomized, Placebo‐Controlled Study

Effects of Vitamin D Therapy on Quality of Life in Patients with Fibromyalgia

The Comparative Economic Burden of Mild, Moderate, and Severe Fibromyalgia: Results from a Retrospective Chart Review and Cross-Sectional Survey of Working-Age U.S. Adults

Contact Info

Product

Resources

About